A proteomics signature of NASH

A proteomics signature of NASH

Global prevalence of nonalcoholic fatty liver disease (NAFLD) is presently 30% and increasing. While the majority of afflicted individuals have a relatively non-progressive form, i.e., nonalcoholic fatty liver (NAFL), a significant subset with nonalcoholic steatohepatitis (NASH) are more likely to progress to cirrhosis.

No pharmacological therapies are currently approved for NAFLD or NASH, and liver histology is the reference standard for identification of those at increased risk of progression. Despite the requirement of liver histology improvement as an endpoint for regulatory approval, several factors limit applicability of biopsy in clinical development, including invasiveness and attendant risks, and sampling and observer variability and costs.

As such, there is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.

Recently, longitudinal assessment of over 5,000 serum proteins in 636 individuals with histologically confirmed NAFLD was used to develop and validate models for all four key individual liver biopsy components (steatosis, hepatocellular ballooning, lobular inflammation, fibrosis) and at-risk NASH, and with sufficient sensitivity and precision to characterize drug intervention-related changes. Taken together, these results support continued validation of such proteomics-based models and their promise to enable a “liquid biopsy” assessment of NAFLD.

Learning objectives

  • Needs and applications of non-invasive testing for liver disease
  • Basics of aptamer-based proteomics assessment and compared to standard clinical blood testing
  • Current applications of proteomics biomarkers for unmet needs in NAFLD and NASH

Headshot of Doctor Sanyal

Arun Sanyal, MBBS, MD

Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Interim Chair and Professor, Division of GI, Hepatology & Nutrition
VCU Health System

A proteomics signature of NASH

A presentation by Arun Sanyal, MD, MBBS

Share with colleagues

More webinars

WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics

Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.

Learn more

WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease 

Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.

Learn more

WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies 

High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.

Learn more

Explore webinars in our interactive viewer